Whither Recombinant Human Leptin Treatment for HIV-Associated Lipoatrophy and the Metabolic Syndrome? (April 2009)
Christos Mantzoros, M.D., an associate professor at Harvard Medical School, offers his take on whether there's a future for leptin replacement as a treatment for metabolic complications in people with HIV. (Editorial originally published in the Journal of Clinical Endocrinology & Metabolism.)
From National AIDS Treatment Advocacy Project
Diabetes Risk Appears Lower for HIV-Positive Patients Than Negative Patients (October 27, 2008)
A large, ongoing study of U.S. military veterans also suggests that the usual risk factors for diabetes, not HIV itself, are the main drivers of diabetes in HIV-positive people. (An interview with Adeel A. Butt, M.D.)
In The 48th Annual ICAAC/IDSA 46th Annual Meeting, from The Body PRO
The Role of Nucleoside Analogs in the Development of Insulin Resistance (July 24, 2007)
NRTIs to date have been thought to contribute to insulin resistance mainly via induction of lipoatrophy. The authors of this paper put forth another potential mechanism based on their findings: that is, zidovudine (AZT, Retrovir)-mediated mitochondrial toxicity in skeletal muscle, adipocytes and hepatocytes. Margaret Hoffman-Terry, M.D., reports.
In 4th International AIDS Society Conference on HIV Pathogenesis, Treatment and Prevention, from The Body PRO
Hepatitis C Coinfection Doesn't Increase the Risk of Lipoatrophy (May 21, 2007)
A pair of new U.S. studies appears to contradict long-held concerns that HIV/hepatitis C-coinfected people have a higher risk of diabetes and lipoatrophy (fat loss).
From aidsmap.com